Histogenics Corporation Form 10-Q Summary
Filing-period note: The supplied filing is for Histogenics Corporation, not Ocugen, Inc. It covers the quarter ended March 31, 2015 and was signed May 14, 2015. The financial statements are unaudited and presented under U.S. GAAP.
Business Context and Reporting Period
Histogenics was a regenerative medicine company developing musculoskeletal tissue-repair products, principally NeoCart, an investigational cartilage implant in a U.S. Phase 3 clinical trial under a Special Protocol Assessment with the FDA. The company had no approved products and had not generated revenue from its planned principal operations.
Management expected to continue incurring significant losses while conducting clinical trials, scaling manufacturing, transferring technology, developing intellectual property, and building public-company infrastructure.
Financial Metrics
| Metric | Q1 2015 | Q1 2014 |
|---|---|---|
| Revenue | No significant product revenue; no clear consolidated revenue value provided | No clear value provided |
| Research and development expense | $5.764 million | $3.374 million |
| General and administrative expense | $2.109 million | $1.799 million |
| Total operating expenses | $7.873 million | $5.173 million |
| Net loss | $7.964 million | $3.437 million |
| Loss per share | $0.60 | $5.90 |
| Net cash used in operating activities | $8.689 million | $5.019 million |
| Capital expenditures | $0.915 million | $0.120 million |
| Cash provided by financing activities | $4.725 million | $(0.235) million |
At March 31, 2015, cash and cash equivalents were $53.181 million, restricted cash was $0.604 million, total assets were $61.580 million, and total liabilities were $10.356 million. The company had $1.737 million of equipment-loan borrowings, including current and long-term portions, and reported compliance with its loan covenants. Accumulated deficit was $141.505 million.
Operating, net loss, and cash-flow margins are not meaningful because the company was a development-stage business with no material commercial revenue.
Material Changes Versus the Prior Comparable Period
- Research and development expense increased $2.390 million, or 71%, primarily because of NeoCart Phase 3 enrollment costs, Lexington facility costs, consulting expenses, and higher headcount.
- General and administrative expense increased $0.310 million, or 17%, driven largely by additional executive and other personnel, insurance, and facility costs, partly offset by lower professional fees.
- Net loss increased $4.527 million, reflecting higher operating expenses and the absence of a $1.738 million fair-value gain recognized in Q1 2014 on liabilities that were settled or terminated in connection with the IPO.
- Cash used in operations increased $3.670 million, or approximately 73%, to $8.689 million.
- Capital expenditures increased $0.795 million, primarily for laboratory equipment and leasehold improvements.
- Financing cash flow was positive in Q1 2015 because of $4.738 million of net proceeds from the underwriters’ partial overallotment exercise.
- Common shares outstanding increased to 13,220,012 at March 31, 2015 from 12,755,012 at December 31, 2014.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
Management stated that existing cash and IPO proceeds were expected to fund projected needs into 2017, but additional capital would be required for continued product development and could be needed sooner. Management cautioned that financing may not be available on acceptable terms or at all.
The company planned to continue progressing toward enrollment of 245 patients in the NeoCart Phase 3 trial by the second quarter of 2016. NeoCart remained unapproved and could not be sold without successful clinical development and regulatory approval.
- Key risks included clinical-trial enrollment, trial results, regulatory approval, manufacturing scale-up and technology transfer, intellectual-property protection, competition, dependence on key personnel and partners, and market acceptance and reimbursement.
- License obligations included potential FDA-approval milestone payments of $3.0 million under the Hydrogel License and $0.3 million under the Tissue Regeneration License, along with royalties and other commitments.
- The company had operating leases extending through 2017 and 2023 and maintained $0.604 million of restricted cash supporting lease-related letters of credit.
- In March 2015, the company issued a warrant for 7,398 common shares at a $9.75 exercise price to its consulting firm in connection with interim CFO services.
- The company reported no material pending legal proceedings, no material changes to previously disclosed risk factors, and no off-balance-sheet arrangements.
- Management concluded that disclosure controls and procedures were effective as of March 31, 2015.
Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is Histogenics Corporation, whereas the request identifies Ocugen, Inc.
- Verify the status, enrollment progress, design, and regulatory conditions of the NeoCart Phase 3 trial.
- Assess whether the stated cash runway into 2017 remains credible given the $8.689 million quarterly operating cash burn and expected expense increases.
- Review future financing needs, potential dilution, debt covenants, and the terms of the equipment loan.
- Evaluate license milestones, royalties, lease obligations, manufacturing commitments, and other contingent cash requirements.
- Review the effect of stock options, warrants, and other potentially dilutive securities on future share count.
- Confirm that the absence of commercial revenue and continuing accumulated losses remains consistent with the company’s current business status.